Cantor Fitzgerald Comments on ABOS FY2025 Earnings

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) – Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Acumen Pharmaceuticals in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings per share of ($1.97) for the year. The consensus estimate for Acumen Pharmaceuticals’ current full-year earnings is ($1.56) per share.

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Acumen Pharmaceuticals in a report on Wednesday, November 13th.

Acumen Pharmaceuticals Stock Performance

ABOS opened at $1.65 on Thursday. Acumen Pharmaceuticals has a 1-year low of $1.53 and a 1-year high of $5.09. The stock has a market cap of $99.13 million, a P/E ratio of -1.20 and a beta of 0.02. The stock’s 50 day simple moving average is $1.95 and its 200 day simple moving average is $2.46. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.43 and a quick ratio of 10.43.

Acumen Pharmaceuticals (NASDAQ:ABOS) last issued its earnings results on Tuesday, November 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14). During the same quarter in the prior year, the firm earned ($0.24) EPS.

Insider Activity

In related news, CFO Matt Zuga sold 28,902 shares of the stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $1.72, for a total transaction of $49,711.44. Following the sale, the chief financial officer now owns 231,744 shares of the company’s stock, valued at $398,599.68. This trade represents a 11.09 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Daniel Joseph Oconnell sold 47,778 shares of the business’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $1.84, for a total transaction of $87,911.52. Following the completion of the transaction, the chief executive officer now directly owns 454,707 shares of the company’s stock, valued at $836,660.88. The trade was a 9.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 131,526 shares of company stock worth $233,124 over the last ninety days. 7.10% of the stock is currently owned by insiders.

Institutional Trading of Acumen Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Franklin Resources Inc. lifted its position in Acumen Pharmaceuticals by 5.4% during the third quarter. Franklin Resources Inc. now owns 3,549,069 shares of the company’s stock worth $8,340,000 after buying an additional 181,451 shares during the period. FMR LLC increased its position in shares of Acumen Pharmaceuticals by 0.3% in the third quarter. FMR LLC now owns 2,028,117 shares of the company’s stock worth $5,030,000 after acquiring an additional 6,014 shares in the last quarter. Geode Capital Management LLC raised its position in Acumen Pharmaceuticals by 6.5% in the third quarter. Geode Capital Management LLC now owns 864,528 shares of the company’s stock valued at $2,144,000 after purchasing an additional 52,395 shares during the period. State Street Corp lifted its position in Acumen Pharmaceuticals by 18.3% during the 3rd quarter. State Street Corp now owns 516,406 shares of the company’s stock worth $1,281,000 after acquiring an additional 79,841 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in shares of Acumen Pharmaceuticals in the second quarter valued at $818,000. Institutional investors and hedge funds own 71.01% of the company’s stock.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.